Clinical trials: Gastroenteritis Escherichia Coli
Diarrhea
Rifaximin for Prevention of Travellers' Diarrhea
The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.
- Trial name
- NCT00742469
- Testing
- Rifaximin
- Where
- Mexico
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Crohn Disease
A Pilot Study of FMT on CD Patients With AIEC
The goal of this pilot study is to test whether Fecal Microbiota Transplant (FMT) would be an effective antibacterial treatment for managing Adherent-invasive Escherichia coli (AIEC) colonization in Crohn's disease (CD) patients.
- Trial name
- NCT05611866
- Testing
- Fecal Microbiota Transplantation
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- Chinese University of Hong Kong
Crohn Disease
Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease
This study will evaluate the safety of oral administration of EcoActive to patients with inactive Crohn's disease and how it affects the levels of AIEC in stool.
- Trial name
- NCT03808103
- Testing
- Bacteriophage preparation
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Intralytix, Inc.
Diarrhea
The Protective Immune Response to Attenuated Enterotoxigenic Escherichia Coli Infection
The existing diarrhoeagenic Escherichia coli (E. coli) challenge model is already suitable for dietary interventions in its current form, targeted to impact on the immediate clinical symptoms upon E. coli infection.
- Trial name
- MIRRE (NCT03596827)
- Testing
- E. coli strain E1392-75-2A dose 1E10 CFU, E. coli strain E1392-75-2A dose 1E9 CFU, E. coli strain E1392-75-2A dose 1E8 CFU
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- NIZO Food Research
Traveler's Diarrhea
PTM202 and Modulation of Host Resistance to Diarrheagenic E. Coli
The APA12/PANTER study is a parallel 3-weeks intervention study. Subjects will be randomly assigned to one of two treatment groups; placebo or PTM202 (n=36 per group).
- Trial name
- APA12/PANTER (NCT03301103)
- Testing
- E. coli strain E1392-75-2A, PTM202
- Where
- Netherlands
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- NIZO Food Research
Crohn's Disease, Ulcerative Colitis
Proteomic Analysis of Crohn's Disease Macrophages in Response or Not to AIEC
The M2iSH laboratory showed with two previous clinical trials that Crohn's Disease (CD) macrophages present i) a defect to control Adherent-Invasive Escherichia coli (AIEC) infection related to polymorphisms associated with CD…
- Trial name
- ROMAN (NCT03404557)
- Testing
- Proteomic analysis
- Where
- France
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Gastroenteritis, Bacterial Infection
The Effect of Probiotics on E. Coli Gastroenteritis
Background: The incidence of gastrointestinal infections is very high. In European countries 10-25% of the population suffers from at least one foodborne infection per year.
- Conditions
- Gastroenteritis, Bacterial Infection, Diarrhea
- Trial name
- PRETEC (NCT01225042)
- Testing
- probiotics
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- NIZO Food Research
Healthy Volunteer
Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge
Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrhea worldwide. Vaccines and therapeutics are under development to prevent ETEC disease in children and travelers.
- Trial name
- NCT03040687
- Testing
- Anti CS6 BSIgG product (Lot PD1601105CS), Anti B7A BSIgG product (Lot PD1601132ET), Bovine Immunoglobin Negative Control (Lot PD161071NC)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Gastroenteritis, Bacterial Infection
The Effect of Probiotics on E. Coli-induced Gastroenteritis
Background: The incidence of gastrointestinal infections is very high. In Western countries at least 30% of the population suffers from at least one food-borne infection per year.
- Conditions
- Gastroenteritis, Bacterial Infection, Diarrhea
- Trial name
- PROTETEC (NCT01709266)
- Testing
- Probiotics
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- NIZO Food Research